|
FY2025
12 months to Dec 28, 2025
|
FY2024
12 months to Dec 29, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Jan 1, 2023
|
FY2021
12 months to Jan 2, 2022
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net earnings (loss) | |||||
| Adjustments to reconcile net earnings to net cash from operating activities: | |||||
| Goodwill impairment charge | |||||
| Asset impairment charge | |||||
| Deferred income taxes | |||||
| Depreciation and amortization | |||||
| Operating lease asset amortization | |||||
| Stock-based compensation | |||||
| Gain on sale of equity securities | |||||
| Unrealized loss on forward contract | |||||
| (Gain) loss on forward contract | |||||
| Provision for credit losses and sales allowances | |||||
| Gain on sale of EMEA staffing operations | |||||
| Gain on sale of assets | |||||
| Loss on investment in Persol Holdings | |||||
| Loss on currency translation from liquidation of subsidiary | |||||
| Gain on foreign currency remeasurement | |||||
| Equity in net earnings of PersolKelly Pte. Ltd. | |||||
| Other, net | |||||
| Changes in operating assets and liabilities, net of acquisitions | |||||
| Changes in operating assets and liabilities, net of acquisitions | |||||
| Accounts receivable | |||||
| Other assets | |||||
| Accounts payable | |||||
| Other liabilities | |||||
| Net cash from (used in) operating activities | |||||
| Cash flows from investing activities: | |||||
| Capital expenditures | |||||
| Proceeds from sale of EMEA staffing operations, net of cash disposed | |||||
| Proceeds from sale of PersolKelly investment | |||||
| Proceeds from sale of assets | |||||
| Acquisition of companies, net of cash received | |||||
| Cash disposed from sale of Russia, net of proceeds | |||||
| Proceeds from sale of Persol Holdings investment | |||||
| Proceeds from sale of equity method investment | |||||
| Proceeds from company-owned life insurance | |||||
| Proceeds from insurance settlement | |||||
| Proceeds from loans to equity affiliate | |||||
| Proceeds from equity securities | |||||
| Other investing activities | |||||
| Net cash (used in) from investing activities | |||||
| Cash flows from financing activities: | |||||
| Net change in short-term borrowings | |||||
| Proceeds from long-term debt | |||||
| Payments on long-term debt | |||||
| Financing lease payments | |||||
| Dividend payments | |||||
| Payments of tax withholding for stock awards | |||||
| Purchase of treasury stock | |||||
| Common Stock | |||||
| Treasury Stock | |||||
| Contingent consideration payments | |||||
| Other financing activities | |||||
| Net cash from (used in) financing activities | |||||
| Effect of exchange rates on cash, cash equivalents and restricted cash | |||||
| Net change in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents and restricted cash at beginning of year | |||||
| Cash, cash equivalents and restricted cash at end of year | |||||
| Cash and equivalents | |||||
| Cash included in assets held for sale | |||||
| Restricted cash included in prepaid expenses and other current assets | |||||
| Restricted cash included in other assets | |||||
| Supplemental cash flow information | |||||
| Interest | |||||
| Income taxes, net | |||||
| Non-cash capital accrual | |||||
Loading...